Healio Visionary Medicine: The Next Era of Retinal Disease Treatment & Patient Adherence – Diabetic Macular Edema (DME)

Key Features

Visionary Medicine: The Next Era of Retinal Disease Treatment & Patient Adherence – Diabetic Macular Edema (DME)
1.0 AMA PRA Category 1 Credit

Topics Covered

Retinal Disease Treatment & Patient Adherence – Diabetic Macular Edema (DME)

Learning Objectives

Upon completion of this activity, participants should be able to:

• Discuss effects of delayed and interrupted treatment for DME.
  
• Evaluate the benefits of newly available anti-VEGF treatment options for DR and DME that may improve visual outcomes.

Target Audience

The target audience includes retina specialists as well as comprehensive ophthalmologists.

Additional credit info

Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and DKBmed LLC. Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Education
Partners designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hours.

PA Continuing Medical Education
Partners has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until 10/28/26. PAs should only claim credit commensurate with the extent of their participation.